Friday, January 4, 2013

Topical Treatments to Reduce Allodynia in Rat Models of CRPS

CREDIT: Rats have feelings too
The Journal of Pain
Volume 14, Issue 1, Pages 66-78, January 2013

Topical Combinations Aimed at Treating Microvascular Dysfunction Reduce Allodynia in Rat Models of CRPS-I and Neuropathic Pain

J. Vaigunda Ragavendran, André Laferrière, Wen Hua Xiao, Gary J. Bennett, Satyanarayana S.V. Padi, Ji Zhang, Terence J. Coderre*

*Contact for reprint requests

Growing evidence indicates that various chronic pain syndromes exhibit tissue abnormalities caused by microvasculature dysfunction in the blood vessels of skin, muscle, or nerve. We tested whether topical combinations aimed at improving microvascular function would relieve allodynia in animal models of complex regional pain syndrome type I (CRPS-I) and neuropathic pain. We hypothesized that topical administration of either α2-adrenergic (α2A) receptor agonists or nitric oxide (NO) donors combined with either phosphodiesterase (PDE) or phosphatidic acid (PA) inhibitors would effectively reduce allodynia in these animal models of chronic pain. Single topical agents produced significant dose-dependent antiallodynic effects in rats with chronic postischemia pain, and the antiallodynic dose-response curves of PDE and PA inhibitors were shifted 2.5- to 10-fold leftward when combined with nonanalgesic doses of α2A receptor agonists or NO donors. Topical combinations also produced significant antiallodynic effects in rats with sciatic nerve injury, painful diabetic neuropathy, and chemotherapy-induced painful neuropathy. These effects were shown to be produced by a local action, lasted up to 6 hours after acute treatment, and did not produce tolerance over 15 days of chronic daily dosing. The present results support the hypothesis that allodynia in animal models of CRPS-I and neuropathic pain is effectively relieved by topical combinations of α2A or NO donors with PDE or PA inhibitors. This suggests that topical treatments aimed at improving microvascular function may reduce allodynia in patients with CRPS-I and neuropathic pain.

This article presents the synergistic antiallodynic effects of combinations of α2A or NO donors with PDE or PA inhibitors in animal models of CRPS-I and neuropathic pain. The data suggest that effective clinical treatment of chronic neuropathic pain may be achieved by therapies that alleviate microvascular dysfunction in affected areas.

NOTE:  It may seem odd to publish the references without providing access to the article text, but many is the time I have found helpful background reading among footnoted/referenced sources. It takes some digging, but can pay off in greater understanding and finding your own "leads" within your particular research interests.


  1. Agrawal RP, Choudhary R, Sharma P, Sharma S, Beniwal R, Kaswan K, et alGlyceryl trinitrate spray in the management of painful diabetic neuropathy: A randomized double blind placebo controlled cross-over study. Diabetes Res Clin Pract.2007;77:161–177
  2. Basile S, Khalil Z, Helme RDSkin vascular reactivity to the neuropeptide substance P in rats with peripheral mononeuropathy. Pain1993;52:217–222
  3. Bassirat M, Helme RD, Khalil ZEffect of chronic sciatic nerve lesion on the neurogenic inflammatory response in intact and acutely injured denervated rat skin. Inflamm Res1996;45:380–385
  4. Baumhaekel M, Scheffler P, Boehm MUse of tadalafil in a patient with a secondary Raynaud's phenomenon not responding to sildenafil. Microvasc Res2005;69:178–179
  5. Berger CC, Bokemeyer C, Schneider M, Kuczyk MA, Schmoll HJSecondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer1995;31A:2229–2238
  6. Bennett GJ, Xie YKA peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain1988;33:87–107
  7. Bhat VB, Madyastha KMAntioxidant and radical scavenging properties of 8-oxo derivatives of xanthine drugs pentoxifylline and lisofylline. Biochem Biophys Res Commun2001;288:1212–1217
  8. Böger RH, Bode-Böger SMEndothelial dysfunction in peripheral arterial occlusive disease: From basic research to clinical use. Vasa1997;26:180–184
  9. Brown MBDermal and Transdermal Drug Delivery Systems: Current and Future Prospects. Drug Delivery2006;13:175–187
  10. Campbell CM, Kipnes MS, Stouch BC, Brady KL, Kelly M, Schmidt WK, et alRandomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain2012;153:1815–1823
  11. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TLQuantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods1994;53:55–63
  12. Chen M, Yang Z, Wu R, Nadler JLLisofylline, a novel antiinflammatory agent, protects pancreatic beta-cells from proinflammatory cytokine damage by promoting mitochondrial metabolism. Endocrinology2002;143:2341–2348
  13. Cocco G, Strozzi C, Haeusler G, Chu D, Amrein R, Padovan GCThe therapeutic value of clonidine in patients with coronary heart disease. Eur J Cardiol1979;10:221–228
  14. Coderre TJ, Xanthos DN, Francis L, Bennett GJChronic post-ischemia pain (CPIP): A novel animal model of complex regional pain syndrome-type I (CRPS-I; reflex sympathetic dystrophy) produced by prolonged hind paw ischemia and reperfusion in the rat. Pain2004;112:94–105
  15. Coon ME, Diegel M, Leshinsky N, Klaus SJSelective pharmacologic inhibition of murine and human IL-12-dependent Th1 differentiation and IL-12 signaling. J Immunol1999;163:6567–6574
  16. Courteix C, Bardin M, Chantelauze C, Lavarenne J, Eschalier AStudy of the sensitivity of the diabetes-induced pain model in rats to a range of analgesics. Pain1994;57:153–160
  17. Cubeddu LXNew alpha 1-adrenergic receptor antagonists for the treatment of hypertension: Role of vascular alpha receptors in the control of peripheral resistance. Am Heart J1988;116:133–162
  18. Davis KD, Treede RD, Raja SN, Meyer RA, Campbell JNTopical application of clonidine relieves hyperalgesia in patients with sympathetically maintained pain. Pain1991;47:309–317
  19. Dawson DL, Cutler BS, Hiatt WR, Hobson RW, Martin JD, Bortey EB, et alA comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med2000;109:523–530
  20. Di Cesare Mannelli L, Zanardelli M, Failli P, Ghelardini COxaliplatin-induced neuropathy: Oxidative stress as pathological mechanism. Protective effect of silibinin. J Pain2012;13:276–284
  21. Doupis J, Lyons TE, Wu S, Gnardellis C, Dinh T, Veves AMicrovascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. J Clin Endocrinol Metab2009;94:2157–2163
  22. Doyle T, Chen Z, Muscoli C, Bryant L, Esposito E, Cuzzocrea S, et alTargeting the overproduction of peroxynitrite for the prevention and reversal of paclitaxel-induced neuropathic pain. J Neurosci2012;32:6149–6160
  23. Du C, Cooper JC, Klaus SJ, Sriram SAmelioration of CR-EAE with lisofylline: Effects on mRNA levels of IL-12 and IFN-gamma in the CNS. J Neuroimmunol2000;110:13–19
  24. Dunbar JC, Reinholt L, Henry RL, Mammen EPlatelet aggregation and disaggregation in the streptozotocin induced diabetic rat: The effect of sympathetic inhibition. Diabetes Res Clin Pract1990;9:265–272
  25. Duthie DJ, Nimmo WSAdverse effects of opioid analgesic drugs. Br J Anaesth1987;59:61–77
  26. Ferry JJ, Shepard JH, Szpunar GJRelationship between contact time of applied dose and percutaneous absorption of minoxidil from a topical solution. J Pharm Sci1990;79:483–486
  27. Giessler C, Wangemann T, Silber RE, Dhein S, Brodde OENoradrenaline-induced contraction of human saphenous vein and human internal mammary artery: Involvement of different alpha-adrenoceptor subtypes. NS Arch Pharmacol.2002;366:104–109
    • Goris RJAConditions associated with impaired oxygen extraction. In:  Guitierrez G,  Vincent JL editor. Tissue Oxygen Utilization. Berlin, DE: Springer Verlag; 1991;p. 350–369
      • Goris RJAReflex sympathetic dystrophy: Model of a severe regional inflammatory response syndrome. World J Surg.1998;22:197–202
      • Gorizontova MP, Mironova IVMicrocirculatory changes during the long-term course of deafferentation pain syndrome.Biull Eksp Biol Med1993;115:233–236
      • Gorizontova MP, Mironova IVThe effect of prophylactic administration of pentoxifylline (trental) on development of a neuropathic pain syndrome and microcirculatory disorders caused by it. Biull Eksp Biol Med1995;119:485–487
      • Groeneweg G, Niehof S, Wesseldijk F, Huygen FJ, Zijlstra FJVasodilative effect of isosorbide dinitrate ointment in complex regional pain syndrome type 1. Clin J Pain2008;24:89–92
      • Guidot DM, Bursten SL, Rice GC, Chaney RB, Singer JW, Repine AJ, et alModulating phosphatidic acid metabolism decreases oxidative injury in rat lungs. Am J Physiol1997;273:L957–L966
      • Hasegawa N, Oka Y, Nakayama M, Berry GJ, Bursten S, Rice G, et alThe effects of post-treatment with lisofylline, a phosphatidic acid generation inhibitor, on sepsis-induced acute lung injury in pigs. Am J Respir Crit Care Med.1997;155:928–936
        • Heerschap A, den Hollander JA, Reynen H, Goris RJMetabolic changes in reflex sympathetic dystrophy: A 31P NMR spectroscopy study. Muscle Nerve1993;16:367–373
        • Heyneman CA, Lawless-Liday C, Wall GCOral versus topical NSAIDs in rheumatic diseases: A comparison. Drugs.2000;60:555–574
        • Higa M, Takasu N, Tamanaha T, Nakamura K, Shimabukuro M, Sasara T, et alNitroglycerin spray rapidly improves pain in a patient with chronic painful diabetic neuropathy. Diabet Med2004;21:1053–1054
        • Horlington M, Watson PAInhibition of 3'5'-cyclic-AMP phosphodiesterase by some platelet aggregation inhibitors. Biochem Pharmacol1970;19:955–956
        • Hrometz SL, Edelmann SE, McCune DF, Olges JR, Hadley RW, Perez DM, et alExpression of multiple alpha1-adrenoceptors on vascular smooth muscle: Correlation with the regulation of contraction. J Pharmacol Exp Ther1999;290:452–463
        • Hyland WTTreating reflex sympathetic dystrophy with transdermal nitroglycerin. Plast Reconstr Surg1989;83:195
        • Ignarro LJ, Napoli C, Loscalzo JNitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: An overview. Circ Res2002;90:21–28
        • Inkster ME, Cotter MA, Cameron NETreatment with the xanthine oxidase inhibitor, allopurinol, improves nerve and vascular function in diabetic rats. Eur J Pharmacol2007;561:63–71
        • Insel J, Halle AA, Mirvis DMEfficacy of pentoxifylline in patients with stable angina pectoris. Angiology1988;39:514–519
        • Jacoby D, Mohler ERDrug treatment of intermittent claudication. Drugs2004;64:1657–1670
        • Jin HY, Lee KA, Song SK, Liu WJ, Choi JH, Song CH, et alSulodexide prevents peripheral nerve damage in streptozotocin induced diabetic rats. Eur J Pharmacol2012;674:217–226
        • Jin SM, Noh CI, Yang SW, Bae EJ, Shin CH, Chung HR, et alEndothelial dysfunction and microvascular complications in type 1 diabetes mellitus. J Korean Med Sci2008;23:77–82
        • Khalil Z, Liu T, Helme RDFree radicals contribute to the reduction in peripheral vascular responses and the maintenance of thermal hyperalgesia in rats with chronic constriction injury. Pain1999;79:31–37
        • Kihara M, Schmelzer JD, Low PAEffect of cilostazol on experimental diabetic neuropathy in the rat. Diabetologia.1995;38:914–918
        • Kirchmair R, Walter DH, Ii M, Rittig K, Tietz AB, Murayama T, et alAntiangiogenesis mediates cisplatin-induced peripheral neuropathy: Attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth. Circulation2005;111:2662–2670
        • Kirchmair R, Tietz AB, Panagiotou E, Walter DH, Silver M, Yoon YS, et alTherapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: Taxol- and thalidomide-induced injury of vasa nervorum is ameliorated by VEGF. Mol Ther2007;15:69–75
        • Koban M, Leis S, Schultze-Mosgau S, Birklein FTissue hypoxia in complex regional pain syndrome. Pain2003;104:149–157
        • Kokesh J, Kazmers A, Zierler REPentoxifylline in the nonoperative management of intermittent claudication. Ann Vasc Surg.1991;5:66–70
        • Kukushkin ML, Smirnova VS, Gorizontova MP, Mironova IV, Zinkevich VAEffect of clofelin and propranolol on the development of neurogenic pain syndrome in rats. Patol Fiziol Eksp Ter1993;4:16–19
        • Kumar N, Laferriere A, Yu JSC, Leavitt A, Coderre TJEvidence that pregabalin reduces neuropathic pain by inhibiting the spinal release of glutamate. J Neurochem2010;113:552–561
        • Kurita GP, Pimenta CACompliance with chronic pain treatment: Study of demographic, therapeutic and psychosocial variables. Arq Neuropsiquiatr2003;61:416–425
        • Laferrière A, Millecamps M, Xanthos DN, Xiao WH, Siau C, de Mos M, et alCutaneous tactile allodynia associated with microvascular dysfunction in muscle. Mol Pain2008;4:49
        • Lekakis JP, Papamichael CM, Vemmos CN, Voutsas AA, Stamatelopoulos SF, Moulopoulos SDPeripheral vascular endothelial dysfunction in patients with angina pectoris and normal coronary arteriograms. J Am Coll Cardiol1998;31:541–546
        • Li C, Sekiyama H, Hayashida M, Takeda K, Sumida T, Sawamura S, et alEffects of topical application of clonidine cream on pain behaviors and spinal Fos protein expression in rat models of neuropathic pain, postoperative pain, and inflammatory pain. Anesthesiology2007;107:486–494
        • Lincoln TMCyclic GMP and mechanisms of vasodilation. Pharmacol Ther1989;41:479–502
        • Liu J, Feng X, Yu M, Xie W, Zhao X, Li W, et alPentoxifylline attenuates the development of hyperalgesia in a rat model of neuropathic pain. Neurosci Lett2007;412:268–272
        • Magnusson M, Bergstrand IC, Björkman S, Heijl A, Roth B, Höglund PA placebo-controlled study of retinal blood flow changes by pentoxifylline and metabolites in humans. Br J Clin Pharmacol2006;61:138–147
        • Magnusson M, Gunnarsson M, Berntorp E, Björkman S, Höglund PEffects of pentoxifylline and its metabolites on platelet aggregation in whole blood from healthy humans. Eur J Pharmacol2008;581:290–295
        • Manahan AP, Burkman KA, Malesker MA, Benecke GWClinical observation on the use of topical nitroglycerin in the management of severe shoulder-hand syndrome. Nebr Med J1993;78:87–89
        • Matsumura H, Jimbo Y, Watanabe KHaemodynamic changes in early phase reflex sympathetic dystrophy. Scandinavian J Plast Reconstr Surg Hand Surg1996;30:133–138
          • Mazoit JXConventional techniques for analgesia: Opioids and non-opioids. Indications, adverse effects and monitoring.Ann Fr Anesth Reanim1998;17:573–584
          • Messin R, Fenyvesi T, Carreer-Bruhwyler F, Crommen J, Chiap P, Hubert P, et alA pilot double-blind randomized placebo-controlled study of molsidomine 16 mg once-a-day in patients suffering from stable angina pectoris: Correlation between efficacy and over time plasma concentrations. Eur J Clin Pharmacol2003;59:227–232
          • Millecamps M, Coderre TJRats with chronic post-ischemia pain (CPIP) exhibit an analgesic sensitivity profile similar to human patients with complex regional pain syndrome type I (CRPS-I). Eur J Pharmacol2008;583:97–102
          • Niehörster M, Schönharting M, Wendel AA novel xanthine derivative counteracting in vivo tumor necrosis factor alpha toxicity in mice. Circ Shock1992;37:270–273
          • Novo S, Abrignani MG, Liquori M, Sangiorgi GB, Strano AThe physiopathology of critical ischemia of the lower limbs. Ann Ital Med Int1993;8(Suppl):66S–70S
            • Oka Y, Hasegawa N, Nakayama M, Murphy GA, Sussman HH, Raffin TASelective downregulation of neutrophils by a phosphatidic acid generation inhibitor in a porcine sepsis model. J Surg Res1999;81:147–155
            • Palos GR, Mendoza TR, Cantor SB, Aday LA, Cleeland CSPerceptions of analgesic use and side effects: What the public values in pain management. J Pain Symptom Manage2004;28:460–473
            • Palmer RM, Ferrige AG, Moncada SNitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature1987;327:524–526
            • Polomano RC, Mannes AJ, Clark US, Bennett GJA painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain2001;94:293–304
            • Quattrini C, Harris ND, Malik RA, Tesfaye SImpaired skin microvascular reactivity in painful diabetic neuropathy. Diabetes Care2007;30:655–659
            • Ragavendran JV, Laferriere A, Khorashadi M, Coderre TJ: The early anti-allodynic effect of pentoxifylline on chronic post-ischemia pain depends on modulation of plantar blood flow. Abstracts of the XIII World Congress on Pain, IASP Press, PT 186, 2010
              • Rice GC, Brown PA, Nelson RJ, Bianco JA, Singer JW, Bursten SProtection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid. Proc Natl Acad Sci USA1994;91:3857–3861
                • Robless P, Mikhailidis DP, Stansby GPCilostazol for peripheral arterial disease. Cochrane Database Syst Rev2007;CD003748
                  • Rybalkin SD, Beavo JAMultiplicity within cyclic nucleotide phosphodiesterases. Biochem Soc Trans1996;24:1005–1009
                  • Schurmann M, Zaspel J, Grandl G, Wipfel A, Christ FAssessment of the peripheral microcirculation using computer-assisted venous congestion plethysmography in post-traumatic complex regional pain syndrome type I. J Vasc Res.2001;38:453–461
                  • Smith RV, Waller ES, Doluisio JT, Bauza MT, Puri SK, Ho I, et alPharmacokinetics of orally administered pentoxifylline in humans. J Pharm Sci1986;75:47–52
                  • Spreux-Varoquaux O, Doll J, Dutot C, Grandjean N, Cordonnier P, Pays M, et alPharmacokinetics of molsidomine and its active metabolite, linsidomine, in patients with liver cirrhosis. Br J Clin Pharmacol1991;32:399–401
                  • Sternitzky R, Seige KClinical investigation of the effects of pentoxifylline in patients with severe peripheral occlusive vascular disease. Curr Med Res Opin1985;9:602–610
                  • Stewart WCEffect and side effects of apraclonidine. Klin Monatsbl Augenheilkd1996;209:A7–A13
                    • Suh KS, Oh SJ, Woo JT, Kim SW, Yang IM, Kim JW, et alEffect of cilostazol on the neuropathies of streptozotocin-induced diabetic rats. Korean J Intern Med1999;14:34–40
                    • Sztajzel J, Mach F, Righetti ARole of the vascular endothelium in patients with angina pectoris or acute myocardial infarction with normal coronary arteries. Postgrad Med J2000;76:16–21
                    • Ting JC, Fukshansky M, Burton AWTreatment of refractory ischemic pain from chemotherapy-induced Raynaud's syndrome with spinal cord stimulation. Pain Pract2007;7:143–146
                    • van der Laan L, ter Laak HJ, Gabreels-Festen A, Gabreels F, Goris RJAComplex regional pain syndrome type I (RSD): Pathology of skeletal muscle and peripheral nerve. Neurology1998;51:20–25
                    • Van Zwieten PA, Thoolen MJ, Timmermans PBThe pharmacology of centrally acting antihypertensive drugs. Br J Clin Pharmacol1983;15(Suppl 4):455S–462S
                    • Waldman SA, Murad FCyclic GMP synthesis and function. Pharmacol Rev1987;39:163–196
                    • Wattanasirichaigoon S, Menconi MJ, Delude RL, Fink MPLisofylline ameliorates intestinal mucosal barrier dysfunction caused by ischemia and ischemia/reperfusion. Shock1999;11:269–275
                    • Waxman K, Daughters K, Aswani S, Rice GLisofylline decreases white cell adhesiveness and improves survival after experimental hemorrhagic shock. Crit Care Med1996;24:1724–1728
                    • Weiss B, Hait WNSelective cyclic nucleotide phosphodiesterase inhibitors as potential therapeutic agents. Ann Rev Pharmacol Toxicol1977;17:441–477
                      • Xanthos DN, Bennett GJ, Coderre TJNorepinephrine-induced nociception and vasoconstrictor hypersensitivity in rats with chronic post-ischemia pain. Pain2008;137:640–651

                      No comments:

                      Post a Comment

                      The Haddock Corporation's newest dictate: Anonymous comments are no longer allowed. It is easy enough to register and just takes a moment. We look forward to hearing from you non-bots and non-spammers!